Addex Therapeutics (NASDAQ:ADXN) Releases Quarterly Earnings Results, Misses Expectations By $1.70 EPS

Posted by Defense World Staff on Oct 2nd, 2024

Addex Therapeutics (NASDAQ:ADXN – Get Free Report) posted its earnings results on Monday. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70), reports. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.26 million. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%.

Addex Therapeutics Stock Performance

Addex Therapeutics stock opened at $9.23 on Wednesday. The stock has a market cap of $9.78 million, a PE ratio of -0.54 and a beta of 1.80. Addex Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $27.90. The firm’s 50-day simple moving average is $9.11 and its 200 day simple moving average is $10.59.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Addex Therapeutics in a research report on Wednesday, August 28th.

Get Our Latest Analysis on ADXN

Addex Therapeutics Company Profile

(Get Free Report)

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.